OptiNose, Inc Expects FY23 XHANCE Net Revenues of $66.0M-$70.0M (Prior $64.0M-$70.0M)
Portfolio Pulse from Benzinga Newsdesk
OptiNose, Inc has updated its FY23 net revenue guidance for XHANCE to be between $66.0M-$70.0M, up from the previous range of $64.0M-$70.0M. The company continues to expect the full year 2023 XHANCE average net revenue per prescription to be approximately $200.
November 09, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OptiNose has raised its FY23 net revenue guidance for XHANCE, which could indicate increased confidence in the product's performance. This may have a positive impact on the company's stock.
OptiNose has raised the lower end of its FY23 net revenue guidance for XHANCE, indicating that the company may be expecting better performance from the product. This could be seen as a positive signal by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100